In vitro C3 deposition on Cryptococcus capsule occurs via multiple complement activation pathways

Molecular Immunology

Volumn 48, Issue 15-16, 2011, Pages 2009-2018

  Mershon Shier, Kileen L ^a,d   Vasuthasawat, Alex ^a   Takahashi, Kazue ^b   Morrison, Sherie L ^a,c   Beenhouwer, David O ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

Complement; Cryptococcus

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CALCIUM; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; EGTAZIC ACID; MANNOSE BINDING LECTIN; MANNOSE BINDING LECTIN A; MANNOSE BINDING LECTIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHELATION; COMPLEMENT ACTIVATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CRYPTOCOCCUS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; FLOW CYTOMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING;

ANIMALS; ANTIGENS, FUNGAL; CELL SEPARATION; COMPLEMENT C3; COMPLEMENT C4; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT PATHWAY, MANNOSE-BINDING LECTIN; CRYPTOCOCCUS; FLOW CYTOMETRY; MANNOSE-BINDING LECTIN; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSCOPY, CONFOCAL; POLYSACCHARIDES;

CRYPTOCOCCUS GATTII; FILOBASIDIELLA NEOFORMANS; MUS;

EID: 80051930807     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2011.06.215     Document Type: Article

References (34)

1. Botto M., Dell'Agnola C., Bygrave A.E., Thompson E.M., Cook H.T., Petry F., Loos M., Pandolfi P.P., Walport M.J. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat. Genet. 1998, 19:56-59.
2. Casadevall A., Perfect J.R. Cryptococcus neoformans 1998, ASM Press, Washington, DC.
3. Diamond R.D., May J.E., Kane M., Frank M.M., Bennett J.E. The role of late complement components and the alternate complement pathway in experimental cryptococcosis. Proc. Soc. Exp. Biol. Med. 1973, 144:312-315.
4. Diamond R.D., May J.E., Kane M.A., Frank M.M., Bennett J.E. The role of the classical and alternate complement pathways in host defenses against Cryptococcus neoformans infection. J. Immunol. 1974, 112:2260-2270.
5. Dromer F., Perronne C., Barge J., Vilde J.L., Yeni P. Role of IgG and complement component C5 in the initial course of experimental cryptococcosis. Clin. Exp. Immunol. 1989, 78:412-417.
6. Endo Y., Nakazawa N., Iwaki D., Takahashi M., Matsushita M., Fujita T. Interactions of ficolin and mannose-binding lectin with fibrinogen/fibrin augment the lectin complement pathway. J. Innate Immun. 2009, 2:33-42.
7. Fischer M.B., Ma M., Goerg S., Zhou X., Xia J., Finco O., Han S., Kelsoe G., Howard R.G., Rothstein T.L., Kremmer E., Rosen F.S., Carroll M.C. Regulation of the B cell response to T-dependent antigens by classical pathway complement. J. Immunol. 1996, 157:549-556.
8. Fujimori Y., Harumiya S., Fukumoto Y., Miura Y., Yagasaki K., Tachikawa H., Fujimoto D. Molecular cloning and characterization of mouse ficolin-A. Biochem. Biophys. Res. Commun. 1998, 244:796-800.
9. Hansen S., Thiel S., Willis A., Holmskov U., Jensenius J.C. Purification and characterization of two mannan-binding lectins from mouse serum. J. Immunol. 2000, 164:2610-2618.
10. Jain N., Fries B.C. Phenotypic switching of Cryptococcus neoformans and Cryptococcus gattii. Mycopathologia 2008, 166:181-188.
11. Kozel T.R. Opsonization and phagocytosis of Cryptococcus neoformans. Arch. Med. Res. 1993, 24:211-218.
12. Kozel T.R., Wilson M.A., Murphy J.W. Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans. Infect. Immun. 1991, 59:3101-3110.
13. Kozel T.R., Wilson M.A., Welch W.H. Kinetic analysis of the amplification phase for activation and binding of C3 to encapsulated and nonencapsulated Cryptococcus neoformans. Infect. Immun. 1992, 60:3122-3127.
14. Laxalt K.A., Kozel T.R. Chemotaxigenesis and activation of the alternative complement pathway by encapsulated and non-encapsulated Cryptococcus neoformans. Infect. Immun. 1979, 26:435-440.
15. Liu H., Jensen L., Hansen S., Petersen S.V., Takahashi K., Ezekowitz A.B., Hansen F.D., Jensenius J.C., Thiel S. Characterization and quantification of mouse mannan-binding lectins (MBL-A and MBL-C) and study of acute phase responses. Scand. J. Immunol. 2001, 53:489-497.
16. Matsumoto M., Fukuda W., Circolo A., Goellner J., Strauss-Schoenberger J., Wang X., Fujita S., Hidvegi T., Chaplin D.D., Colten H.R. Abrogation of the alternative complement pathway by targeted deletion of murine factor B. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:8720-8725.
17. Meri S., Pangburn M.K. A mechanism of activation of the alternative complement pathway by the classical pathway: protection of C3b from inactivation by covalent attachment to C4b. Eur. J. Immunol. 1990, 20:2555-2561.
18. Mershon K.L., Vasuthasawat A., Lawson G.W., Morrison S.L., Beenhouwer D.O. Role of complement in protection against Cryptococcus gattii infection. Infect. Immun. 2009, 77:1061-1070.
19. Panepinto J.C., Komperda K.W., Hacham M., Shin S., Liu X., Williamson P.R. Binding of serum mannan binding lectin to a cell integrity-defective Cryptococcus neoformans ccr4Delta mutant. Infect. Immun. 2007, 75:4769-4779.
20. Rhodes J.C. Contribution of complement component C5 to the pathogenesis of experimental murine cryptococcosis. Sabouraudia 1985, 23:225-234.
21. Rhodes J.C., Wicker L.S., Urba W.J. Genetic control of susceptibility to Cryptococcus neoformans in mice. Infect. Immun. 1980, 29:494-499.
22. Runza V.L., Schwaeble W., Mannel D.N. Ficolins: novel pattern recognition molecules of the innate immune response. Immunobiology 2008, 213:297-306.
23. Schelenz S., Malhotra R., Sim R.B., Holmskov U., Bancroft G.J. Binding of host collectins to the pathogenic yeast Cryptococcus neoformans: human surfactant protein D acts as an agglutinin for acapsular yeast cells. Infect. Immun. 1995, 63:3360-3366.
24. Selander B., Martensson U., Weintraub A., Holmstrom E., Matsushita M., Thiel S., Jensenius J.C., Truedsson L., Sjoholm A.G. Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J. Clin. Invest. 2006, 116:1425-1434.
25. Shapiro S., Beenhouwer D.O., Feldmesser M., Taborda C., Carroll M.C., Casadevall A., Scharff M.D. Immunoglobulin G monoclonal antibodies to Cryptococcus neoformans protect mice deficient in complement component C3. Infect. Immun. 2002, 70:2598-2604.
26. Shi L., Takahashi K., Dundee J., Shahroor-Karni S., Thiel S., Jensenius J.C., Gad F., Hamblin M.R., Sastry K.N., Ezekowitz R.A. Mannose-binding lectin-deficient mice are susceptible to infection with Staphylococcus aureus. J. Exp. Med. 2004, 199:1379-1390.
27. Stephen C., Lester S., Black W., Fyfe M., Raverty S. Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia. Can. Vet. J. 2002, 43:792-794.
28. Takahashi K., Gordon J., Liu H., Sastry K.N., Epstein J.E., Motwani M., Laursen I., Thiel S., Jensenius J.C., Carroll M., Ezekowitz R.A. Lack of mannose-binding lectin-A enhances survival in a mouse model of acute septic peritonitis. Microbes Infect. 2002, 4:773-784.
29. Takahashi M., Ishida Y., Iwaki D., Kanno K., Suzuki T., Endo Y., Homma Y., Fujita T. Essential role of mannose-binding lectin-associated serine protease-1 in activation of the complement factor D. J. Exp. Med. 2010, 207:29-37.
30. Truelsen K., Young T., Kozel T.R. In vivo complement activation and binding of C3 to encapsulated Cryptococcus neoformans. Infect. Immun. 1992, 60:3937-3939.
31. Washburn R.G., Bryant-Varela B.J., Julian N.C., Bennett J.E. Differences in Cryptococcus neoformans capsular polysaccharide structure influence assembly of alternative complement pathway C3 convertase on fungal surfaces. Mol. Immunol. 1991, 28:465-470.
32. Wessels M.R., Butko P., Ma M., Warren H.B., Lage A.L., Carroll M.C. Studies of group B streptococcal infection in mice deficient in complement component C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:11490-11494.
33. Young B.J., Kozel T.R. Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans. Infect. Immun. 1993, 61:2966-2972.
34. Zaragoza O., Fries B.C., Casadevall A. Induction of capsule growth in Cryptococcus neoformans by mammalian serum and CO(2). Infect. Immun. 2003, 71:6155-6164.